Antibody responses to 43 and 48 kDa antigens of blood-stage Plasmodium berghei in Balb/c mice

被引：3

作者：

Bagai U. ^{[1
]}

Pawar A. ^{[1
]}

Kumar V. ^{[1
]}

机构：

[1] Parasitology Laboratory, Department of Zoology, Panjab University

来源：

Journal of Parasitic Diseases | 2010年 / 34卷 / 2期

关键词：

43; kDa; 48; Antibody; Immunity; Malaria; Plasmodium; Vaccine;

D O I：

10.1007/s12639-010-0012-5

中图分类号：

学科分类号：

摘要：

Progress towards a vaccine against malaria is advancing rapidly with several candidate antigens being tested for their safety and efficacy. In present investigation, two polypeptides (43 and 48 kDa) of Plasmodium berghei (NK-65) were identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Immunogenicity and protective efficacy of both these polypeptides formulated in saponin has been compared in Balb/c mice against challenge infection with P. berghei. Antibody responses were evaluated by indirect fluorescent antibody test and enzyme-linked immunosorbent assay. Merozoite invasion inhibition assay and challenge infections revealed that 48 kDa antigen is better immunogen as compared to 43 kDa and provide better protection against rodent malaria infection. © 2010 Indian Society for Parasitology.

引用

页码：68 / 74

页数：6

共 37 条

[21]

Laemmli U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T<sub>4</sub>, Nature, 227, pp. 680-685, (1970)

[22]

Lowry O.H., Rasebrough N.J., Farr A.L., Randall R.J., Protein measurement with phenol reagent, J Biol Chem, 193, pp. 265-275, (1951)

[23]

Mahanty S., Saul A., Miller L.H., Progress in the development of recombinant and synthetic blood-stage malaria vaccines, J Exp Biol, 206, pp. 3781-3788, (2003)

[24]

Manuel E.P., Patarroyo A.M., Emerging rules for subunit based multi antigenic multistage chemically synthesized vaccines, Acc Chem Res, 41, pp. 377-386, (2008)

[25]

Mata E., Carcaboso A.M., Hernandez R.M., Igartua M., Corradin G., Pedraz J.L., Adjuvant activity of polymer microparticles and montanide ISA 720 on immune responses to P. falciparum MSP2 long synthetic peptides in mice, Vaccine, 25, pp. 877-885, (2007)

[26]

Miller L.H., Aikawa M., Dvorak J.A., Malaria Plasmodium knowlesi merozoites: Immunity and the surface coat, J Immunol, 114, pp. 1237-1242, (1975)

[27]

Miller L.H., Baruch D.I., Marsh K., Doumbo O.K., The pathogenic basis of malaria, Nature, 415, pp. 673-679, (2002)

[28]

Ockenhouse C.F., Angov E., Kester K.E., Diggs C., Et al., Phase 1 safety and immunogenicity trial of FMP1/AS02A, a P. falciparum MSP-1 asexual blood stage vaccine, Vaccine, 24, pp. 3009-3017, (2006)

[29]

Oeuvray C., Bouharoun-Tayoun H., Grass-Masse H., Lepers J.P., Ralamboranto L., Tartar A., Druilhe P., A novel merozoite surface antigen of P. falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies, Mem Inst Oswaldo Cruz, 89, pp. 77-80, (1994)

[30]

Playfair J.H.L., de Souza J.B., Vaccination of mice against malaria with soluble antigen I. The effect of detergent route of infection and adjuvant, Parasite Immunol, 8, pp. 409-414, (1987)

← 1 2 3 4 →